Russell Investments Group Ltd. Has $11.18 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Russell Investments Group Ltd. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 86.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,681 shares of the medical device company's stock after selling 898,563 shares during the period. Russell Investments Group Ltd.'s holdings in DexCom were worth $11,183,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of DXCM. Versant Capital Management Inc acquired a new stake in DexCom during the fourth quarter valued at approximately $25,000. Private Trust Co. NA boosted its holdings in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC boosted its position in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new position in DexCom during the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DXCM. Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Mizuho initiated coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price for the company. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $99.00.

DexCom Stock Up 2.2 %

Shares of DXCM traded up $1.50 during mid-day trading on Tuesday, hitting $68.89. 2,750,380 shares of the company's stock were exchanged, compared to its average volume of 4,188,608. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a market cap of $27.01 billion, a price-to-earnings ratio of 48.17, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The firm has a fifty day moving average of $76.49 and a two-hundred day moving average of $76.68.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.